EGFR and nonpapillary renal cell carcinoma: Importantly, the inhibitory effects of PRDX1 knockdown on ccRCC could be attenuated by EGF activation <i>in vitro</i>, as well as the oncogenic functions enhanced by increasing PRDX1 was blocked by gefitinib, a specific inhibitor of EGFR.